Zusammenfassung
Der plötzliche Herztod ist in der überwiegenden Zahl der Fälle bedingt durch ventrikuläre Tachyarrhythmien. Implantierbare Kardioverter/Defibrillatoren (ICD) stellen heute eine evidenzbasierte und gut etablierte Methode zur Prävention des plötzlichen Herztods dar. Für Patienten, die die Kriterien für eine leitliniengerechte ICD-Implantation nicht erfüllen und dennoch ein erhöhtes, z. B. transientes, Risiko für den plötzlichen Herztod haben, wurde der tragbare Kardioverter/Defibrillator („wearable cardioverter/defibrillator“ [WCD]) etabliert. Zahlreiche Studien konnten die Sicherheit und Effektivität des WCD belegen, auch wenn randomisierte Studien zum Nachweis einer Reduktion der Mortalität und Prognoseverbesserung noch fehlen. Diese Übersichtsarbeit liefert einen Überblick über die aktuelle Datenlage, die Indikationen für den WCD sowie dessen potenzielle Risiken und Komplikationen.
Abstract
In the majority of cases sudden cardiac death (SCD) is caused by ventricular tachyarrhythmia. Implantable cardioverter-defibrillators (ICD) represent an evidence-based and established method for prevention of SCD. For patients who do not fulfill the criteria for guideline-conform implantation of an ICD but still have an increased, e.g. transient risk for SCD, a wearable cardioverter-defibrillator (WCD) vest was developed to temporarily prevent SCD. Numerous studies have shown the safety and efficacy of the WCD, although there is still a gap in evidence concerning a reduction in overall mortality and improvement in prognosis. This article gives an overview on the currently available literature on WCD, the indications, potential risks and complications.
Literatur
Auricchio A, Klein H, Geller CJ et al (1998) Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol 81:1253–1256
Bauersachs J, Arrigo M, Hilfiker-Kleiner D et al (2016) Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. doi:10.1002/ejhf.586
Chung MK, Szymkiewicz SJ, Shao M et al (2010) Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol 56:194–203. doi:10.1016/j.jacc.2010.04.016
Dillon KA, Szymkiewicz SJ, Kaib TE (2010) Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm. J Electrocardiol 43:63–67. doi:10.1016/j.jelectrocard.2009.05.010
Duncker D, Haghikia A, König T et al (2014) Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16:1331–1336. doi:10.1002/ejhf.188
Duncker D, König T, Hohmann S, Veltmann C (2015) Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies. Herzschrittmacherther Elektrophysiol 26:82–93. doi:10.1007/s00399-015-0372-8
Duncker D, Veltman C (2016) The wearable cardioverter/defibrillator – toy or tool? J Atr Fibrillation 8:69–77
Epstein AE, Abraham WT, Bianco NR et al (2013) Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol 62:2000–2007. doi:10.1016/j.jacc.2013.05.086
Feldman AM, Klein H, Tchou P et al (2004) Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: Results of the WEARIT/BIROAD. Pacing Clin Electrophysiol 27:4–9
Goldenberg I, Vyas AK, Hall WJ et al (2008) Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51:288–296. doi:10.1016/j.jacc.2007.08.058
Healy CA, Carrillo RG (2015) Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation. Heart Rhythm 12:1565–1573. doi:10.1016/j.hrthm.2015.03.061
Kutyifa V, Moss AJ, Klein H et al (2015) Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry). Circulation 132(17):1613–1619. doi:10.1161/CIRCULATIONAHA.115.015677
Martens E, Sinner MF, Siebermair J et al (2014) Incidence of sudden cardiac death in Germany: results from an emergency medical service registry in Lower Saxony. Europace 16:1752–1758. doi:10.1093/europace/euu153
Neuzner J, Gradaus R (2015) ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection. Herzschrittmacherther Elektrophysiol 26:75–81. doi:10.1007/s00399-015-0371-9
Piccini JP, Allen LA, Kudenchuk PJ et al (2016) Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: A science advisory from the American Heart Association. Circulation 133:1715–1727. doi:10.1161/CIR.0000000000000394
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J:ehw128–ehw85. doi:10.1093/eurheartj/ehw128
Priori SG, Blomström-Lundqvist C, Mazzanti A et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36:2793–2867. doi:10.1093/eurheartj/ehv316
Prochnau D, Surber R, Kuehnert H et al (2010) Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction. Clin Res Cardiol 99:129–131. doi:10.1007/s00392-009-0093-2
Rao M, Goldenberg I, Moss AJ et al (2011) Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol 108:1632–1638. doi:10.1016/j.amjcard.2011.07.021
Reek S, Geller JC, Meltendorf U et al (2003) Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol 26:2016–2022
Saltzberg MT, Szymkiewicz S, Bianco NR (2012) Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 18:21–27. doi:10.1016/j.cardfail.2011.09.004
Schwab JO, Bänsch D, Israel C, Nowak B (2015) Statement on the use of wearable cardioverter defibrillators. Kardiologe 9:165–170. doi:10.1007/s12181-015-0651-y
Sheppard R, Mather PJ, Alexis JD et al (2012) Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2. J Card Fail 18:675–681. doi:10.1016/j.cardfail.2012.07.004
Sjöblom J, Muhrbeck J, Witt N et al (2014) Evolution of left ventricular ejection fraction after acute myocardial infarction: Implications for implantable cardioverter-defibrillator eligibility. Circulation 130:743–748. doi:10.1161/CIRCULATIONAHA.114.009924
Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12:767–778. doi:10.1093/eurjhf/hfq120
Tanawuttiwat T, Garisto JD, Salow A et al (2014) Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator. Pacing Clin Electrophysiol 37:562–568. doi:10.1111/pace.12319
van der Heijden AC, Borleffs CJW, Buiten MS et al (2015) The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm 12:1169–1176. doi:10.1016/j.hrthm.2015.02.035
Wan C, Herzog CA, Zareba W, Szymkiewicz SJ (2014) Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 19:247–257. doi:10.1111/anec.12119
Zishiri ET, Williams S, Cronin EM et al (2013) Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythmia Electrophysiol 6:117–128. doi:10.1161/CIRCEP.112.973552
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
D. Duncker erhielt Vortragshonorare und Reisekostenunterstützung von ZOLL, C. Veltmann erhielt Vortragshonorare, Reisekostenunterstützung und Forschungsmittel von ZOLL. J. Bauersachs gibt an, dass kein Interessenkonflikt besteht.
Bei diesem Beitrag handelt es sich um eine Übersichtsarbeit. Es werden keine bislang unpublizierten Studiendaten präsentiert.
Additional information
Redaktion
H. Haller, Hannover
G. Hasenfuß, Göttingen
Rights and permissions
About this article
Cite this article
Duncker, D., Bauersachs, J. & Veltmann, C. Die Defibrillatorweste. Internist 57, 864–870 (2016). https://doi.org/10.1007/s00108-016-0110-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-016-0110-2